{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:54:49Z","timestamp":1793840089375,"version":"4.6.1"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009526","name":"Amrita Vishwa Vidyapeetham University","doi-asserted-by":"publisher","award":["Project ID: K-PHAR-20-627"],"award-info":[{"award-number":["Project ID: K-PHAR-20-627"]}],"id":[{"id":"10.13039\/100009526","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11033-021-06752-9","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T17:48:20Z","timestamp":1634752100000},"page":"8075-8095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets"],"prefix":"10.1007","volume":"48","author":[{"given":"Ayana R.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswathy R.","family":"Devan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyalakshmi","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balachandran S.","family":"Vinod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7726-7219","authenticated-orcid":false,"given":"Lekshmi R.","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"issue":"68","key":"6752_CR1","first-page":"394","volume":"2018","author":"B Freddie","year":"2018","unstructured":"Freddie B, Ferlay J (2018) Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CAAC 2018(68):394\u2013424","journal-title":"CAAC"},{"issue":"5","key":"6752_CR2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00109-016-1393-4","volume":"94","author":"J Qiao","year":"2016","unstructured":"Qiao J, Liu Z, Fu YX (2016) Adapting conventional cancer treatment for immunotherapy. J Mol Med 94(5):489\u2013495","journal-title":"J Mol Med"},{"issue":"1","key":"6752_CR3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1):59\u201373","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"6752_CR4","first-page":"381","volume":"82","author":"FJ Berkey","year":"2010","unstructured":"Berkey FJ (2010) Managing the adverse effects of radiation therapy. Am Fam Phys 82(4):381\u2013388","journal-title":"Am Fam Phys"},{"issue":"3","key":"6752_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","volume":"9","author":"R Baskar","year":"2012","unstructured":"Baskar R, Lee KA, Yeo R, Yeoh KW (2012) Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9(3):193","journal-title":"Int J Med Sci"},{"issue":"268","key":"6752_CR6","first-page":"1","volume":"38","author":"K Stephan","year":"2019","unstructured":"Stephan K, Matthias I, Sebastian K (2019) Advances in cancer immunotherapy 2019 \u2013 latest trends. Exp Clin Cancer Res 38(268):1\u201311","journal-title":"Exp Clin Cancer Res"},{"issue":"5","key":"6752_CR7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","volume":"25","author":"H Sato","year":"2020","unstructured":"Sato H, Okonogi N, Nakano T (2020) Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol 25(5):801\u2013809","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"6752_CR8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","volume":"36","author":"K Vermeulen","year":"2003","unstructured":"Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36(3):131\u2013149","journal-title":"Cell Prolif"},{"issue":"7776","key":"6752_CR9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E (2019) Harnessing innate immunity in cancer therapy. Nature 574(7776):45\u201356","journal-title":"Nature"},{"issue":"3","key":"6752_CR10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","volume":"15","author":"EA Mesri","year":"2014","unstructured":"Mesri EA, Feitelson MA, Munger K (2014) Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 15(3):266\u2013282","journal-title":"Cell Host Microbe"},{"issue":"11","key":"6752_CR11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nri3754","volume":"14","author":"T Kambayashi","year":"2014","unstructured":"Kambayashi T, Laufer TM (2014) Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? Nat Rev Immunol 14(11):719\u2013730","journal-title":"Nat Rev Immunol"},{"key":"6752_CR12","doi-asserted-by":"crossref","first-page":"e49020","DOI":"10.7554\/eLife.49020","volume":"8","author":"S Wang","year":"2019","unstructured":"Wang S, He Z, Wang X, Li H, Liu XS (2019) Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife 8:e49020","journal-title":"Elife"},{"key":"6752_CR13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2016.09.010","volume":"68","author":"M De Charette","year":"2016","unstructured":"De Charette M, Marabelle A, Houot R (2016) Turning tumor cells into antigen presenting cells: the next step to improve cancer immunotherapy? Eur J Cancer 68:134\u2013147","journal-title":"Eur J Cancer"},{"issue":"9","key":"6752_CR14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.tibtech.2014.06.007","volume":"32","author":"LJ Eggermont","year":"2014","unstructured":"Eggermont LJ, Paulis LE, Tel J, Figdor CG (2014) Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol 32(9):456\u2013465","journal-title":"Trends Biotechnol"},{"issue":"8","key":"6752_CR15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG, Serody JS (2019) Alternative tumor-specific antigens. Nat Rev Cancer 19(8):465\u2013478","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"6752_CR16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cdp.2003.12.006","volume":"28","author":"JY Zhang","year":"2004","unstructured":"Zhang JY (2004) Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detect Prev 28(2):114\u2013118","journal-title":"Cancer Detect Prev"},{"issue":"2","key":"6752_CR17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2017.07.138","volume":"147","author":"RT Fortner","year":"2017","unstructured":"Fortner RT, Damms-Machado A, Kaaks R (2017) Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol 147(2):465\u2013480","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6752_CR18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00006676-200301000-00009","volume":"26","author":"T Akashi","year":"2003","unstructured":"Akashi T, Oimomi H, Nishiyama KI, Nakashima M, Arita Y, Sumii T, Kimura T, Ito T, Nawata H, Watanabe T (2003) Expression and diagnostic evaluation of the human tumor\u2013associated antigen RCAS1 in pancreatic cancer. Pancreas 26(1):49\u201355","journal-title":"Pancreas"},{"issue":"10","key":"6752_CR19","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1074\/mcp.R600010-MCP200","volume":"5","author":"CA Casiano","year":"2006","unstructured":"Casiano CA, Mediavilla-Varela M, Tan EM (2006) Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteom 5(10):1745\u20131759","journal-title":"Mol Cell Proteom"},{"issue":"7","key":"6752_CR20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.12-7-873","volume":"12","author":"A Ribas","year":"2007","unstructured":"Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte\u2013associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12(7):873\u2013883","journal-title":"Oncologist"},{"key":"6752_CR21","doi-asserted-by":"crossref","first-page":"7819520","DOI":"10.1155\/2018\/7819520","volume":"2018","author":"H Degroote","year":"2018","unstructured":"Degroote H, Van Dierendonck A, Geerts A, Van Vlierberghe H, Devisscher L (2018) Preclinical and clinical therapeutic strategies affecting tumor-associated macrophages in hepatocellular carcinoma. J Immunol Res 2018:7819520","journal-title":"J Immunol Res"},{"key":"6752_CR22","doi-asserted-by":"crossref","first-page":"4273943","DOI":"10.1155\/2016\/4273943","volume":"2016","author":"PH Pandya","year":"2016","unstructured":"Pandya PH, Murray ME (2016) The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res 2016:4273943","journal-title":"J Immunol Res"},{"key":"6752_CR23","doi-asserted-by":"crossref","first-page":"794528","DOI":"10.1155\/2015\/794528","volume":"2015","author":"MA McNamara","year":"2015","unstructured":"McNamara MA, Nair SK, Holl EK (2015) RNA-based vaccines in cancer immunotherapy. J Immunol Res 2015:794528","journal-title":"J Immunol Res"},{"key":"6752_CR24","doi-asserted-by":"crossref","first-page":"583287","DOI":"10.3389\/fimmu.2020.583287","volume":"11","author":"R Minati","year":"2020","unstructured":"Minati R, Perreault C, Thibault P (2020) A roadmap toward the definition of actionable tumor-specific antigens. Front Immunol 11:583287","journal-title":"Front Immunol"},{"key":"6752_CR25","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3389\/fimmu.2019.01856","volume":"10","author":"JC Castle","year":"2019","unstructured":"Castle JC, Uduman M, Pabla S, Stein RB, Buell JS (2019) Mutation-derived neoantigens for cancer immunotherapy. Front Immunol 10:1856","journal-title":"Front Immunol"},{"issue":"1","key":"6752_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0686-1","volume":"12","author":"T Jiang","year":"2019","unstructured":"Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, Ren S, Zhou C (2019) Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol 12(1):1\u20133","journal-title":"J Hematol Oncol"},{"issue":"4","key":"6752_CR27","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers3043856","volume":"3","author":"S Lee","year":"2011","unstructured":"Lee S, Margolin K (2011) Cytokines in cancer immunotherapy. Cancers 3(4):3856\u20133893","journal-title":"Cancers"},{"key":"6752_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2018.00001","volume":"8","author":"HT Marshal","year":"2018","unstructured":"Marshal HT, Djamgoz MBA (2018) Immuno-oncology: emerging targets and combination therapies. Front Oncol 8:1\u201329","journal-title":"Front Oncol"},{"issue":"1","key":"6752_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40883-019-00113-6","volume":"6","author":"N Parayath","year":"2020","unstructured":"Parayath N, Padmakumar S, Nair SV, Menon D, Amiji MM (2020) Strategies for targeting cancer immunotherapy through modulation of the tumor microenvironment. Regener Eng Transl Med 6(1):29\u201349","journal-title":"Regener Eng Transl Med"},{"key":"6752_CR30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fimmu.2018.00527","volume":"9","author":"A Albini","year":"2018","unstructured":"Albini A, Bruno A, Noonan DM, Mortara L (2018) Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol 9:527","journal-title":"Front Immunol"},{"issue":"12","key":"6752_CR31","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","volume":"18","author":"NL Syn","year":"2017","unstructured":"Syn NL, Teng MW, Mok TS, Soo RA (2017) De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 18(12):e731\u2013e741","journal-title":"Lancet Oncol"},{"key":"6752_CR32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219\u2013242","journal-title":"Immunol Rev"},{"issue":"1","key":"6752_CR33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05919.x","volume":"1217","author":"BT Fife","year":"2011","unstructured":"Fife BT, Pauken KE (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann NY Acad Sci 1217(1):45\u201359","journal-title":"Ann NY Acad Sci"},{"issue":"8","key":"6752_CR34","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4161\/onci.21335","volume":"1","author":"L Zitvogel","year":"2012","unstructured":"Zitvogel L, Kroemer G (2012) Targeting PD-1\/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1(8):1223\u20131225","journal-title":"Oncoimmunology"},{"issue":"2","key":"6752_CR35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1590\/S1415-47572007000300003","volume":"30","author":"K Braun-Prado","year":"2007","unstructured":"Braun-Prado K, Petzl-Erler ML (2007) Programmed cell death 1 gene (PDCD1) polymorphism and pemphigus foliaceus (fogo selvagem) disease susceptibility. Genet Mol Biol 30(2):314\u2013321","journal-title":"Genet Mol Biol"},{"issue":"8","key":"6752_CR36","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","volume":"11","author":"Y Ohigashi","year":"2005","unstructured":"Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8):2947\u20132953","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6752_CR37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173(2):945\u2013954","journal-title":"J Immunol"},{"issue":"41","key":"6752_CR38","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.2174\/1381612824666181112114958","volume":"24","author":"P Jiao","year":"2018","unstructured":"Jiao P, Geng Q, Jin P, Su G, Teng H, Dong J, Yan B (2018) Small molecules as PD-1\/PD-L1 pathway modulators for cancer immunotherapy. Curr Pharm Des 24(41):4911\u20134920","journal-title":"Curr Pharm Des"},{"issue":"3","key":"6752_CR39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261\u2013268","journal-title":"Nat Immunol"},{"issue":"5","key":"6752_CR40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nri1349","volume":"4","author":"L Chen","year":"2004","unstructured":"Chen L (2004) Co-inhibitory molecules of the B7\u2013CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5):336\u2013347","journal-title":"Nat Rev Immunol"},{"key":"6752_CR41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fonc.2019.00047","volume":"9","author":"H Yang","year":"2019","unstructured":"Yang H, Zhou X, Sun L, Mao Y (2019) Correlation between PD-L2 expression and clinical outcome in solid cancer patients: a meta-analysis. Front Oncol 9:47","journal-title":"Front Oncol"},{"key":"6752_CR42","doi-asserted-by":"crossref","first-page":"656340","DOI":"10.1155\/2012\/656340","volume":"2012","author":"EN Rozali","year":"2012","unstructured":"Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ (2012) Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012:656340","journal-title":"Clin Dev Immunol"},{"key":"6752_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.12.002","volume":"57","author":"E Maverakis","year":"2015","unstructured":"Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, Raychaudhuri S, Ruhaak LR, Lebrilla CB (2015) Glycans in the immune system and the altered glycan theory of autoimmunity: a critical review. J Autoimmunity 57:1\u20133","journal-title":"J Autoimmunity"},{"issue":"4","key":"6752_CR44","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783\u2013801","journal-title":"Cell"},{"issue":"1","key":"6752_CR45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.it.2005.11.005","volume":"27","author":"D Van Duin","year":"2006","unstructured":"Van Duin D, Medzhitov R, Shaw AC (2006) Triggering TLR signaling in vaccination. Trends Immunol 27(1):49\u201355","journal-title":"Trends Immunol"},{"issue":"12","key":"6752_CR46","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1128\/IAI.68.12.6883-6890.2000","volume":"68","author":"S Tsuji","year":"2000","unstructured":"Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T (2000) Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immunity 68(12):6883\u20136890","journal-title":"Infect Immunity"},{"issue":"14","key":"6752_CR47","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa052916","volume":"355","author":"PS Creticos","year":"2006","unstructured":"Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D (2006) Immunotherapy with a ragweed\u2013Toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355(14):1445\u20131455","journal-title":"N Engl J Med"},{"issue":"5","key":"6752_CR48","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","volume":"13","author":"H Kanzler","year":"2007","unstructured":"Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13(5):552\u2013559","journal-title":"Nat Med"},{"issue":"4","key":"6752_CR49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.immuni.2007.10.002","volume":"27","author":"TD Kanneganti","year":"2007","unstructured":"Kanneganti TD, Lamkanfi M, N\u00fa\u00f1ez G (2007) Intracellular NOD-like receptors in host defense and disease. Immunity 27(4):549\u2013559","journal-title":"Immunity"},{"key":"6752_CR50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fimmu.2014.00327","volume":"5","author":"M Saxena","year":"2014","unstructured":"Saxena M, Yeretssian G (2014) NOD-like receptors: master regulators of inflammation and cancer. Front Immunol 5:327","journal-title":"Front Immunol"},{"key":"6752_CR51","first-page":"73","volume":"53","author":"K Kondelkova","year":"2010","unstructured":"Kondelkova K, Vokurkov\u00e1 D, Krejsek J, Borsk\u00e1 L, Fiala Z, Ctirad A (2010) Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. Acta Medica 53:73\u201377","journal-title":"Acta Medica"},{"key":"6752_CR52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminoncol.2013.12.004","volume":"41","author":"LD Mary","year":"2014","unstructured":"Mary LD (2014) Mechanism of action of immunotherapy. Semin Oncol 41:3\u201313","journal-title":"Semin Oncol"},{"issue":"5","key":"6752_CR53","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaci.2017.02.013","volume":"139","author":"BP Davis","year":"2017","unstructured":"Davis BP, Ballas ZK (2017) Biologic response modifiers: indications, implications, and insights. J Allergy Clin Immunol 139(5):1445\u20131456","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"6752_CR54","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"8","key":"6752_CR55","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-004-0653-2","volume":"54","author":"KL Knutson","year":"2005","unstructured":"Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54(8):721\u2013728","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"6752_CR56","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1002\/jcb.26663","volume":"119","author":"S Upadhyay","year":"2018","unstructured":"Upadhyay S, Sharma N, Gupta KB, Dhiman M (2018) Role of immune system in tumor progression and carcinogenesis. J Cell Biochem 119(7):5028\u20135042","journal-title":"J Cell Biochem"},{"issue":"1","key":"6752_CR57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"RA Weinberg","year":"2000","unstructured":"Weinberg RA, Hanahan D (2000) The hallmarks of cancer. Cell 100(1):57\u201370","journal-title":"Cell"},{"issue":"2","key":"6752_CR58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2009.11.001","volume":"31","author":"M Sauerborn","year":"2010","unstructured":"Sauerborn M, Brinks V, Jiskoot W, Schellekens H (2010) Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31(2):53\u201359","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"6752_CR59","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tibs.2006.01.006","volume":"31","author":"SK Calderwood","year":"2006","unstructured":"Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31(3):164\u2013172","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"6752_CR60","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/08820130009062296","volume":"29","author":"XY Wang","year":"2000","unstructured":"Wang XY, Kaneko Y, Repasky E, Subjeck JR (2000) Heat shock proteins and cancer immunotherapy. Immunol Investig 29(2):131\u2013137","journal-title":"Immunol Investig"},{"issue":"9","key":"6752_CR61","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3390\/ijms18091978","volume":"18","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Burns TF (2017) Targeting heat shock proteins in cancer: a promising therapeutic approach. Int J Mol Sci 18(9):1978","journal-title":"Int J Mol Sci"},{"key":"6752_CR62","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3267207","author":"JK Das","year":"2019","unstructured":"Das JK, Xiong X, Ren X, Yang JM, Song J (2019) Heat shock proteins in cancer immunotherapy. J Oncol. https:\/\/doi.org\/10.1155\/2019\/3267207","journal-title":"J Oncol"},{"issue":"3","key":"6752_CR63","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1582-4934.2008.00273.x","volume":"12","author":"D Lanneau","year":"2008","unstructured":"Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C (2008) Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 12(3):743\u2013761","journal-title":"J Cell Mol Med"},{"issue":"1","key":"6752_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-1536-5-7","volume":"5","author":"A Vidyasagar","year":"2012","unstructured":"Vidyasagar A, Wilson NA, Djamali A (2012) Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair 5(1):1\u20137","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"1","key":"6752_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07882-8","volume":"10","author":"B Eftekharzadeh","year":"2019","unstructured":"Eftekharzadeh B, Banduseela VC, Chiesa G, Mart\u00ednez-Crist\u00f3bal P, Rauch JN, Nath SR, Schwarz DM, Shao H, Marin-Argany M, Di Sanza C, Giorgetti E (2019) Hsp70 and Hsp40 inhibit an inter-domain interaction necessary for transcriptional activity in the androgen receptor. Nat Commun 10(1):1\u20134","journal-title":"Nat Commun"},{"issue":"6","key":"6752_CR66","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00018-004-4464-6","volume":"62","author":"MP Mayer","year":"2005","unstructured":"Mayer MP, Bukau B (2005) Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci 62(6):670\u2013684","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"6752_CR67","first-page":"2031","volume":"29","author":"C Moser","year":"2009","unstructured":"Moser C, Lang SA, Stoeltzing O (2009) Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res 29(6):2031\u20132042","journal-title":"Anticancer Res"},{"issue":"3","key":"6752_CR68","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/14712598.1.3.539","volume":"1","author":"MM Caudill","year":"2001","unstructured":"Caudill MM, Li Z (2001) HSPPC-96: a personalised cancer vaccine. Expert Opin Biol Ther 1(3):539\u2013547","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"6752_CR69","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/ijc.21795","volume":"118","author":"H Geng","year":"2006","unstructured":"Geng H, Zhang GM, Xiao H, Yuan Y, Li D, Zhang H, Qiu H, He YF, Feng ZH (2006) HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int Jn Cancer 118(11):2657\u20132664","journal-title":"Int Jn Cancer"},{"issue":"5","key":"6752_CR70","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.4049\/jimmunol.0901235","volume":"183","author":"J Gong","year":"2009","unstructured":"Gong J, Zhu B, Murshid A, Adachi H, Song B, Lee A, Liu C, Calderwood SK (2009) T cell activation by heat shock protein 70 vaccine requires TLR signaling and scavenger receptor expressed by endothelial cells-1. J Immunol 183(5):3092\u20133098","journal-title":"J Immunol"},{"issue":"1","key":"6752_CR71","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4049\/jimmunol.0902255","volume":"184","author":"J Gong","year":"2010","unstructured":"Gong J, Zhang Y, Durfee J, Weng D, Liu C, Koido S, Song B, Apostolopoulos V, Calderwood SK (2010) A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol 184(1):488\u2013496","journal-title":"J Immunol"},{"issue":"1","key":"6752_CR72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/or.2013.2445","volume":"30","author":"J Zong","year":"2013","unstructured":"Zong J, Wang C, Liu B, Liu M, Cao Y, Sun X, Yao Y, Sun G (2013) Human hsp70 and HPV16 oE7 fusion protein vaccine induces an effective antitumor efficacy. Oncol Rep 30(1):407\u2013412","journal-title":"Oncol Rep"},{"issue":"1","key":"6752_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-43556-1","volume":"9","author":"M Klimczak","year":"2019","unstructured":"Klimczak M, Biecek P, Zylicz A, Zylicz M (2019) Heat shock proteins create a signature to predict the clinical outcome in breast cancer. Sci Rep 9(1):1\u20135","journal-title":"Sci Rep"},{"issue":"1","key":"6752_CR74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ph13010009","volume":"13","author":"S Kumar","year":"2020","unstructured":"Kumar S, Principe DR, Singh SK, Viswakarma N, Sondarva G, Rana B, Rana A (2020) Mitogen-activated protein kinase inhibitors and t-cell-dependent immunotherapy in cancer. Pharmaceuticals 13(1):9","journal-title":"Pharmaceuticals"},{"issue":"11","key":"6752_CR75","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1586\/erv.11.124","volume":"10","author":"A Murshid","year":"2011","unstructured":"Murshid A, Gong J, Stevenson MA, Calderwood SK (2011) Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev Vaccines 10(11):1553\u20131568","journal-title":"Expert Rev Vaccines"},{"key":"6752_CR76","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.isci.2018.10.021","volume":"9","author":"D Xiong","year":"2018","unstructured":"Xiong D, Wang Y, Singavi AK, Mackinnon AC, George B, You M (2018) Immunogenomic landscape contributes to hyperprogressive disease after anti-PD-1 immunotherapy for cancer. iScience 9:258\u2013277","journal-title":"iScience"},{"issue":"9\u201310","key":"6752_CR77","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/1947601913486349","volume":"4","author":"C Tournier","year":"2013","unstructured":"Tournier C (2013) The 2 faces of JNK signaling in cancer. Genes Cancer 4(9\u201310):397\u2013400","journal-title":"Genes Cancer"},{"issue":"11","key":"6752_CR78","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ni1528","volume":"8","author":"CR Roy","year":"2007","unstructured":"Roy CR, Mocarski ES (2007) Pathogen subversion of cell-intrinsic innate immunity. Nat Immunol 8(11):1179\u20131187","journal-title":"Nat Immunol"},{"issue":"9","key":"6752_CR79","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","volume":"13","author":"JS Arthur","year":"2013","unstructured":"Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13(9):679\u2013692","journal-title":"Nat Rev Immunol"},{"key":"6752_CR80","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3389\/fimmu.2020.00624","volume":"11","author":"ND Bhattacharyya","year":"2020","unstructured":"Bhattacharyya ND, Feng CG (2020) Regulation of T helper cell fate by TCR signal strength. Front Immunol 11:624","journal-title":"Front Immunol"},{"issue":"4","key":"6752_CR81","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/eji.200939513","volume":"40","author":"K Ohkusu-Tsukada","year":"2010","unstructured":"Ohkusu-Tsukada K, Toda M, Udono H, Kawakami Y, Takahashi K (2010) Targeted inhibition of IL-10-secreting CD25\u2212 Treg via p38 MAPK suppression in cancer immunotherapy. Eur J Immunol 40(4):1011\u20131021","journal-title":"Eur J Immunol"},{"issue":"11","key":"6752_CR82","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1365-2222.2006.02606.x","volume":"36","author":"S Romagnani","year":"2006","unstructured":"Romagnani S (2006) Regulation of the T cell response. Clin Exp Allergy 36(11):1357\u20131366","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"6752_CR83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tox.2004.08.015","volume":"206","author":"F Boisl\u00e8ve","year":"2005","unstructured":"Boisl\u00e8ve F, Kerdine-R\u00f6mer S, Pallardy M (2005) Implication of the MAPK pathways in the maturation of human dendritic cells induced by nickel and TNF-\u03b1. Toxicology 206(2):233\u2013244","journal-title":"Toxicology"},{"issue":"2","key":"6752_CR84","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/path.4259","volume":"232","author":"B Homet","year":"2014","unstructured":"Homet B, Ribas A (2014) New drug targets in metastatic melanoma. J Pathol 232(2):134\u2013141","journal-title":"J Pathol"},{"key":"6752_CR85","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fonc.2019.00248","volume":"9","author":"Y Shimizu","year":"2019","unstructured":"Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T (2019) Next-generation cancer immunotherapy targeting glypican-3. Front Oncol 9:248","journal-title":"Front Oncol"},{"issue":"3","key":"6752_CR86","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","volume":"47","author":"M Ho","year":"2011","unstructured":"Ho M, Kim H (2011) Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 47(3):333\u2013338","journal-title":"Eur J Cancer"},{"issue":"19","key":"6752_CR87","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/1538-7445.AM2014-418","volume":"74","author":"TL Trinh","year":"2014","unstructured":"Trinh TL, Puszyk W, Liu C (2014) Epigenetic regulation of glypican-3 in hepatocellular carcinoma. Cancer Res 74(19):418","journal-title":"Cancer Res"},{"issue":"4","key":"6752_CR88","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/hep.25891","volume":"56","author":"L Li","year":"2012","unstructured":"Li L, Jin R, Zhang X, Lv F, Liu L, Liu D, Liu K, Li N, Chen D (2012) Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology 56(4):1380\u20131390","journal-title":"Hepatology"},{"issue":"20","key":"6752_CR89","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","volume":"18","author":"DM Miller","year":"2012","unstructured":"Miller DM, Thomas SD, Islam A, Muench D, Sedoris K (2012) c-Myc and cancer metabolism. Clin Cancer Res 18(20):5546\u20135553","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6752_CR90","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/cas.13485","volume":"109","author":"Y Shimizu","year":"2018","unstructured":"Shimizu Y, Suzuki T, Yoshikawa T, Tsuchiya N, Sawada Y, Endo I, Nakatsura T (2018) Cancer immunotherapy-targeted glypican-3 or neoantigens. Cancer Sci 109(3):531\u2013541","journal-title":"Cancer Sci"},{"key":"6752_CR91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/1568009620666201116113334","volume":"21","author":"C Ratan","year":"2020","unstructured":"Ratan C, Cicily KD, Nair B, Nath LR (2020) MUC glycoproteins: potential biomarkers and molecular targets for cancer therapy. Curr Cancer Drug Targets 21:132","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"6752_CR92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrc1251","volume":"4","author":"MA Hollingsworth","year":"2004","unstructured":"Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45\u201360","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"6752_CR93","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1471-4922(03)00122-3","volume":"19","author":"DM Moncada","year":"2003","unstructured":"Moncada DM, Kammanadiminti SJ, Chadee K (2003) Mucin and Toll-like receptors in host defense against intestinal parasites. Trends Parasitol 19(7):305\u2013311","journal-title":"Trends Parasitol"},{"key":"6752_CR94","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2013.00248","volume":"4","author":"RS Mahla","year":"2013","unstructured":"Mahla RS, Reddy CM, Prasad D, Kumar H (2013) Sweeten PAMPs: role of sugar complexed PAMPs in innate immunity and vaccine biology. Front Immunol 4:248","journal-title":"Front Immunol"},{"issue":"3","key":"6752_CR95","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1165\/rcmb.2007-0336RC","volume":"38","author":"K Ueno","year":"2008","unstructured":"Ueno K, Koga T, Kato K, Golenbock DT, Gendler SJ, Kai H, Kim KC (2008) MUC1 mucin is a negative regulator of toll-like receptor signaling. Am J Respir Cell Mol Biol 38(3):263\u2013268","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"6752_CR96","first-page":"2856","volume":"54","author":"Y Kotera","year":"1994","unstructured":"Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54(11):2856\u20132860","journal-title":"Cancer Res"},{"issue":"24","key":"6752_CR97","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1073\/pnas.0801340105","volume":"105","author":"D Shental-Bechor","year":"2008","unstructured":"Shental-Bechor D, Levy Y (2008) Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc Natl Acad Sci 105(24):8256\u20138261","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"6752_CR98","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1042\/BST20170400","volume":"46","author":"J Taylor-Papadimitriou","year":"2018","unstructured":"Taylor-Papadimitriou J, Burchell JM, Graham R, Beatson R (2018) Latest developments in MUC1 immunotherapy. Biochem Soc Trans 46(3):659\u2013668","journal-title":"Biochem Soc Trans"},{"key":"6752_CR99","doi-asserted-by":"crossref","first-page":"871936","DOI":"10.1155\/2013\/871936","volume":"2013","author":"D Roulois","year":"2013","unstructured":"Roulois D, Gr\u00e9goire M, Fonteneau JF (2013) MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. BioMed Res Int 2013:871936","journal-title":"BioMed Res Int"},{"issue":"7","key":"6752_CR100","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1134\/S0006297919070083","volume":"84","author":"MS Syrkina","year":"2019","unstructured":"Syrkina MS, Rubtsov MA (2019) MUC1 in cancer immunotherapy: new hope or phantom menace? Biochem Mosc 84(7):773\u2013781","journal-title":"Biochem Mosc"},{"key":"6752_CR101","unstructured":"Collins NB, Al Abosy R, Miller B, Bi K, Manguso R, Yates K, Haining WN. PI3K activated tumors evade tumor immunity by promoting an inhibitory myeloid microenvironment"},{"issue":"6908","key":"6752_CR102","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nature01112","volume":"419","author":"V Groh","year":"2002","unstructured":"Groh V, Wu J, Yee C, Spies T (2002) Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419(6908):734\u2013738","journal-title":"Nature"},{"issue":"3","key":"6752_CR103","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/med.20143","volume":"29","author":"A Nicolini","year":"2009","unstructured":"Nicolini A, Carpi A (2009) Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev 29(3):436\u2013471","journal-title":"Med Res Rev"},{"issue":"3","key":"6752_CR104","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1189\/jlb.0807561","volume":"84","author":"MS Thomas","year":"2008","unstructured":"Thomas MS, Mitchell JS, DeNucci CC, Martin AL, Shimizu Y (2008) The p110\u03b3 isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J Leukoc Biol 84(3):814\u2013823","journal-title":"J Leukoc Biol"},{"issue":"2","key":"6752_CR105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bcp.2009.08.006","volume":"79","author":"CH Tang","year":"2010","unstructured":"Tang CH, Yamamoto A, Lin YT, Fong YC, Tan TW (2010) Involvement of matrix metalloproteinase-3 in CCL5\/CCR5 pathway of chondrosarcomas metastasis. Biochem Pharmacol 79(2):209\u2013217","journal-title":"Biochem Pharmacol"},{"key":"6752_CR106","first-page":"91","volume-title":"Seminars in cancer biology","author":"JS O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell JS, Massi D, Teng MW, Mandala M (2018) PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. In: Kim JB (ed) Seminars in cancer biology, vol 48. Academic Press, Cambridge, pp 91\u2013103"},{"issue":"1","key":"6752_CR107","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2119\/molmed.2015.00083","volume":"21","author":"A Lin","year":"2015","unstructured":"Lin A, Yan WH (2015) Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med 21(1):782\u2013791","journal-title":"Mol Med"},{"issue":"8","key":"6752_CR108","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1582-4934.2009.00917.x","volume":"14","author":"A Lin","year":"2010","unstructured":"Lin A, Chen HX, Zhu CC, Zhang X, Xu HH, Zhang JG, Wang Q, Zhou WJ, Yan WH (2010) Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med 14(8):2162\u20132171","journal-title":"J Cell Mol Med"},{"issue":"9","key":"6752_CR109","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.168.9.4772","volume":"168","author":"H Wiendl","year":"2002","unstructured":"Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M (2002) A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168(9):4772\u20134780","journal-title":"J Immunol"},{"issue":"26","key":"6752_CR110","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1182\/blood-2010-07-294389","volume":"117","author":"S Agaugu\u00e9","year":"2011","unstructured":"Agaugu\u00e9 S, Carosella ED, Rouas-Freiss N (2011) Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1\/Th17. Blood 117(26):7021\u20137031","journal-title":"Blood"},{"issue":"1","key":"6752_CR111","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ijc.26375","volume":"131","author":"A Lin","year":"2012","unstructured":"Lin A, Zhang X, Xu HH, Xu DP, Ruan YY, Yan WH (2012) HLA-G expression is associated with metastasis and poor survival in the Balb\/c nu\/nu murine tumor model with ovarian cancer. Int J Cancer 131(1):150\u2013157","journal-title":"Int J Cancer"},{"issue":"1","key":"6752_CR112","first-page":"699","volume":"15","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Yu S, Han Y, Wang Y, Sun Y (2018) Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis\/treatment. Oncol Lett 15(1):699\u2013709","journal-title":"Oncol Lett"},{"issue":"2","key":"6752_CR113","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/bjc.2013.696","volume":"110","author":"EC Zeestraten","year":"2014","unstructured":"Zeestraten EC, Reimers MS, Saadatmand S, Dekker JT, Liefers GJ, Van Den Elsen PJ, Van De Velde CJ, Kuppen PJ (2014) Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer 110(2):459\u2013468","journal-title":"Br J Cancer"},{"issue":"4","key":"6752_CR114","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1535-6108(04)00079-0","volume":"5","author":"DM Brown","year":"2004","unstructured":"Brown DM, Ruoslahti E (2004) Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 5(4):365\u2013374","journal-title":"Cancer Cell"},{"issue":"2","key":"6752_CR115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3892\/ol.2012.734","volume":"4","author":"X Chen","year":"2012","unstructured":"Chen X, Dong K, Long M, Lin F, Wang X, Wei J, Ren J, Zhang H (2012) Serum anti-AEG-1 auto-antibody is a potential novel biomarker for malignant tumors. Oncol Lett 4(2):319\u2013323","journal-title":"Oncol Lett"},{"key":"6752_CR116","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fonc.2019.00349","volume":"9","author":"G Dhiman","year":"2019","unstructured":"Dhiman G, Srivastava N, Goyal M, Rakha E, Lothion-Roy J, Mongan NP, Miftakhova RR, Khaiboullina SF, Rizvanov AA, Baranwal M (2019) Metadherin: a therapeutic target in multiple cancers. Front Oncol 9:349","journal-title":"Front Oncol"},{"issue":"8","key":"6752_CR117","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/sj.onc.1210713","volume":"27","author":"SG Lee","year":"2008","unstructured":"Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB (2008) Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 27(8):1114\u20131121","journal-title":"Oncogene"},{"issue":"50","key":"6752_CR118","doi-asserted-by":"crossref","first-page":"21300","DOI":"10.1073\/pnas.0910936106","volume":"106","author":"L Emdad","year":"2009","unstructured":"Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, Fisher PB (2009) Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci 106(50):21300\u201321305","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"6752_CR119","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1097\/MD.0000000000000502","volume":"94","author":"GC Zhu","year":"2015","unstructured":"Zhu GC, Yu CY, She L, Tan HL, Li G, Ren SL, Su ZW, Wei M, Huang DH, Tian YQ, Su RN (2015) Metadherin regulation of vascular endothelial growth factor expression is dependent upon the PI3K\/Akt pathway in squamous cell carcinoma of the head and neck. Medicine 94(6):e502","journal-title":"Medicine"},{"issue":"2","key":"6752_CR120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12032-014-0479-5","volume":"32","author":"PP Li","year":"2015","unstructured":"Li PP, Feng LL, Chen N, Ge XL, Lv X, Lu K, Ding M, Yuan D, Wang X (2015) Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt\/\u03b2-catenin pathway. Med Oncol 32(2):21","journal-title":"Med Oncol"},{"issue":"3","key":"6752_CR121","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1172\/JCI36460","volume":"119","author":"BK Yoo","year":"2009","unstructured":"Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, Mills AS, Waxman S, Fisher RA, Llovet JM, Fisher PB (2009) Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Investig 119(3):465\u2013477","journal-title":"J Clin Investig"},{"issue":"4","key":"6752_CR122","first-page":"4795","volume":"8","author":"X Shi","year":"2015","unstructured":"Shi X, Wang X (2015) The role of MTDH\/AEG-1 in the progression of cancer. Int J Clin Exp Med 8(4):4795","journal-title":"Int J Clin Exp Med"},{"issue":"12","key":"6752_CR123","doi-asserted-by":"crossref","first-page":"e29363","DOI":"10.1371\/journal.pone.0029363","volume":"6","author":"Y Zhao","year":"2011","unstructured":"Zhao Y, Kong X, Li X, Yan S, Yuan C, Hu W, Yang Q (2011) Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells. PLoS ONE 6(12):e29363","journal-title":"PLoS ONE"},{"issue":"4","key":"6752_CR124","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s11033-020-05334-5","volume":"47","author":"MT Abdel Ghafar","year":"2020","unstructured":"Abdel Ghafar MT, Gharib F, Abdel-Salam S, Elkhouly RA, Elshora A, Shalaby KH, El-Guindy D, El-Rashidy MA, Soliman NA, Abu-Elenin MM, Allam AA (2020) Role of serum Metadherin mRNA expression in the diagnosis and prediction of survival in patients with colorectal cancer. Mol Biol Rep 47(4):2509","journal-title":"Mol Biol Rep"},{"issue":"6","key":"6752_CR125","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3892\/mco.2014.392","volume":"2","author":"Z Wang","year":"2014","unstructured":"Wang Z, Wei YB, Gao YL, Yan B, Yang JR, Guo Q (2014) Metadherin in prostate, bladder, and kidney cancer: a systematic review. Mol Clin Oncol 2(6):1139\u20131144","journal-title":"Mol Clin Oncol"},{"issue":"9","key":"6752_CR126","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/1348-0421.12436","volume":"60","author":"G Dhiman","year":"2016","unstructured":"Dhiman G, Lohia N, Jain S, Baranwal M (2016) Metadherin peptides containing CD4+ and CD8+ T cell epitopes as a therapeutic vaccine candidate against cancer. Microbiol Immunol 60(9):646\u2013652","journal-title":"Microbiol Immunol"},{"issue":"6","key":"6752_CR127","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/imt.14.35","volume":"6","author":"T Oh","year":"2014","unstructured":"Oh T, Ivan ME, Sun MZ, Safaee M, Fakurnejad S, Clark AJ, Sayegh ET, Bloch O, Parsa AT (2014) PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. Immunotherapy 6(6):737\u2013753","journal-title":"Immunotherapy"},{"issue":"10","key":"6752_CR128","first-page":"1773","volume":"9","author":"Z Hongming","year":"2018","unstructured":"Hongming Z, Jibei C (2018) Current status and future directions of cancer immunotherapy. JCA 9(10):1773\u20131781","journal-title":"JCA"},{"issue":"6","key":"6752_CR129","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","volume":"53","author":"E Bonavita","year":"2020","unstructured":"Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, Mensurado S, Moeini A, Flanagan E, Bell CR, Chiang SC (2020) Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity 53(6):1215\u20131229","journal-title":"Immunity"},{"issue":"3","key":"6752_CR130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.25100\/cm.v48i3.2997","volume":"48","author":"MR Martha","year":"2017","unstructured":"Martha MR, Estuardo AC, Augusto RM (2017) Immunotherapy and gene therapy as novel treatments for cancer. Colomb Med 48(3):138\u2013147","journal-title":"Colomb Med"},{"issue":"39","key":"6752_CR131","first-page":"1","volume":"11","author":"A Julian","year":"2018","unstructured":"Julian A, Marin A, Bhagirathbhai D, Aixa E (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11(39):1\u201320","journal-title":"J Hematol Oncol"},{"key":"6752_CR132","first-page":"1","volume":"8","author":"O Hashem","year":"2017","unstructured":"Hashem O, Samaresh S, Rami A (2017) PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:1\u201315","journal-title":"Front Pharmacol"},{"key":"6752_CR133","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nbt.4090","volume":"36","author":"K Garber","year":"2018","unstructured":"Garber K (2018) Driving T-cell Immunotherapy to solid tumors. Nat Biotechnol 36:215\u2013219","journal-title":"Nat Biotechnol"},{"issue":"1","key":"6752_CR134","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"IB Elizabeth","year":"2016","unstructured":"Elizabeth IB, Anupam D (2016) CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98\u2013106","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"6752_CR135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L (2020) Monoclonal antibodies in cancer therapy. Antibodies 9(3):34","journal-title":"Antibodies"},{"issue":"4","key":"6752_CR136","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","volume":"7","author":"S Li","year":"2005","unstructured":"Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4):301\u2013311","journal-title":"Cancer Cell"},{"issue":"1","key":"6752_CR137","first-page":"25","volume":"34","author":"D Patel","year":"2009","unstructured":"Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X (2009) Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR\/HER-2 heterodimerization and activation. Int J Oncol 34(1):25\u201332","journal-title":"Int J Oncol"},{"issue":"4905","key":"6752_CR138","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712","journal-title":"Science"},{"issue":"3","key":"6752_CR139","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1368-7646(03)00040-2","volume":"6","author":"JS Chen","year":"2003","unstructured":"Chen JS, Lan K, Hung MC (2003) Strategies to target HER2\/neu overexpression for cancer therapy. Drug Resist Updates 6(3):129\u2013136","journal-title":"Drug Resist Updates"},{"issue":"1","key":"6752_CR140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-018-0034-5","volume":"4","author":"J Wang","year":"2019","unstructured":"Wang J, Xu B (2019) Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther 4(1):1\u201322","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"6752_CR141","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90(6):2188\u20132195","journal-title":"Blood"},{"issue":"255","key":"6752_CR142","first-page":"1","volume":"38","author":"R Anand","year":"2019","unstructured":"Anand R (2019) Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 38(255):1\u201312","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"6752_CR143","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","volume":"45","author":"G Kimiz","year":"2018","unstructured":"Kimiz G, Gulce I, Biray AC (2018) Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep 45(6):2935\u20132940","journal-title":"Mol Biol Rep"},{"issue":"1","key":"6752_CR144","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","volume":"19","author":"AN Miliotou","year":"2018","unstructured":"Miliotou AN, Papadopoulou LC (2018) CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 19(1):5\u201318","journal-title":"Curr Pharm Biotechnol"},{"issue":"165","key":"6752_CR145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Nair S (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(165):1\u201311","journal-title":"Exp Mol Med"},{"key":"6752_CR146","first-page":"1","volume":"3","author":"W Xiuyan","year":"2016","unstructured":"Xiuyan W, Isabelle R (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncol 3:1\u20137","journal-title":"Mol Ther Oncol"},{"issue":"8","key":"6752_CR147","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1592\/phco.31.8.813","volume":"31","author":"AE Hammerstrom","year":"2011","unstructured":"Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P (2011) Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 31(8):813\u2013828","journal-title":"Pharmacotherapy"},{"issue":"2","key":"6752_CR148","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/vaccines3020467","volume":"3","author":"PL Lollini","year":"2015","unstructured":"Lollini PL, Cavallo F, Nanni P, Quaglino E (2015) The promise of preventive cancer vaccines. Vaccines 3(2):467\u2013489","journal-title":"Vaccines"},{"issue":"3","key":"6752_CR149","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ (2018) Towards personalized, tumor-specific, therapeutic vaccines for cancer. Nat Rev Immunol 18(3):168\u2013182","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"6752_CR150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc.2016.16","volume":"16","author":"SH Van der Burg","year":"2016","unstructured":"Van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16(4):219\u2013233","journal-title":"Nat Rev Cancer"},{"key":"6752_CR151","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/bs.ai.2015.12.001","volume":"130","author":"KK Wong","year":"2016","unstructured":"Wong KK, Li WA, Mooney DJ, Dranoff G (2016) Advances in therapeutic cancer vaccines. Adv Immunol 130:191\u2013249","journal-title":"Adv Immunol"},{"key":"6752_CR152","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.coi.2018.03.001","volume":"51","author":"H Maeng","year":"2018","unstructured":"Maeng H, Terabe M, Berzofsky JA (2018) Cancer vaccines: translation from mice to human clinical trials. Curr Opin Immunol 51:111\u2013122","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"6752_CR153","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nri.2017.140","volume":"18","author":"OJ Finn","year":"2018","unstructured":"Finn OJ (2018) The dawn of vaccines for cancer prevention. Nat Rev Immunol 18(3):183\u2013194","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"6752_CR154","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/hv.19795","volume":"8","author":"T Gardner","year":"2012","unstructured":"Gardner T, Elzey B, Hahn NM (2012) Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccines Immunother 8(4):534\u2013539","journal-title":"Hum Vaccines Immunother"},{"key":"6752_CR155","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fimmu.2019.00467","volume":"10","author":"A Mougel","year":"2019","unstructured":"Mougel A, Terme M, Tanchot C (2019) Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade. Front Immunol 10:467","journal-title":"Front Immunol"},{"issue":"9","key":"6752_CR156","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/ijc.25863","volume":"129","author":"A Bose","year":"2011","unstructured":"Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ (2011) Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129(9):2158\u20132170","journal-title":"Int J Cancer"},{"key":"6752_CR157","first-page":"65","volume":"7","author":"F Oliver","year":"2015","unstructured":"Oliver F, Nikhil V (2015) Immunotherapy for bladder cancer. Res Rep Urol 7:65\u201379","journal-title":"Res Rep Urol"},{"key":"6752_CR158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.00001","volume":"10","author":"M Alice","year":"2019","unstructured":"Alice M, Magali T, Corinne T (2019) Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade. Front Immunol 10:1\u201327","journal-title":"Front Immunol"},{"key":"6752_CR159","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC (2019) Cytokines in clinical cancer immunotherapy. BJC 120:6\u201315","journal-title":"BJC"},{"issue":"4","key":"6752_CR160","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers3043856","volume":"3","author":"L Sylvia","year":"2011","unstructured":"Sylvia L, Kim M (2011) Cytokines in cancer immunotherapy. Cancers 3(4):3856\u20133893","journal-title":"Cancers"},{"issue":"22","key":"6752_CR161","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.3390\/ijms20225579","volume":"20","author":"J Zaheer","year":"2019","unstructured":"Zaheer J, Kim H, Lee YJ, Kim JS, Lim SM (2019) Combination radioimmunotherapy strategies for solid tumors. Int J Mol Sci 20(22):5579","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6752_CR162","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"SM Larson","year":"2015","unstructured":"Larson SM, Carrasquillo JA (2015) Radioimmunotherapy of human tumors. Nat Rev Cancer 15(6):347\u2013360","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"6752_CR163","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000486788","volume":"94","author":"SD Puvvada","year":"2018","unstructured":"Puvvada SD, Guill\u00e9n-Rodr\u00edguez JM, Yan J, Incl\u00e1n L, Heard K, Rivera XI, Anwer F, Mahadevan D, Schatz JH, Persky DO (2018) Yttrium-90-Ibritumomab tiuxetan (Zevalin\u00ae) radioimmunotherapy after cytoreduction with ESHAP chemotherapy in patients with relapsed follicular non-Hodgkin lymphoma: final results of a phase II study. Oncology 94(5):274\u2013280","journal-title":"Oncology"},{"issue":"31","key":"6752_CR164","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.18632\/oncotarget.26893","volume":"10","author":"AF Di Maria Jiang","year":"2019","unstructured":"Di Maria Jiang AF, Nguyen LT, Neel BG, Sacher A, Rottapel R, Wang BX, Ohashi PS, Sridhar SS (2019) Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. Oncotarget 10(31):2947","journal-title":"Oncotarget"},{"issue":"1","key":"6752_CR165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5266-4","volume":"19","author":"H Bahig","year":"2019","unstructured":"Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, Nguyen-Tan FP, Souli\u00e8res D, Guertin L, Filion E, Christopoulos A (2019) Phase I\/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. BMC Cancer 19(1):1\u20135","journal-title":"BMC Cancer"},{"issue":"8","key":"6752_CR166","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(19)30306-7","volume":"20","author":"SD Karam","year":"2019","unstructured":"Karam SD, Raben D (2019) Radioimmunotherapy for the treatment of head and neck cancer. Lancet Oncol 20(8):e404\u2013e416","journal-title":"Lancet Oncol"},{"issue":"6","key":"6752_CR167","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3390\/cancers13061374","volume":"13","author":"C Corr\u00f2","year":"2021","unstructured":"Corr\u00f2 C, Dutoit V, Koessler T (2021) Emerging trends for radio-immunotherapy in rectal cancer. Cancers 13(6):1374","journal-title":"Cancers"},{"issue":"2","key":"6752_CR168","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ijc.20217","volume":"111","author":"GJ Bauerschmitz","year":"2004","unstructured":"Bauerschmitz GJ, Kanerva A, Wang M, Herrmann I, Shaw DR, Strong TV, Desmond R, Rein DT, Dall P, Curiel DT, Hemminki A (2004) Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int J Cancer 111(2):303\u2013309","journal-title":"Int J Cancer"},{"key":"6752_CR169","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bmb\/62.1.149","volume":"62","author":"D Said","year":"2002","unstructured":"Said D, Anne CA (2002) Cancer vaccines and immunotherapy. Br Med Bull 62:149\u2013162","journal-title":"Br Med Bull"},{"issue":"140","key":"6752_CR170","first-page":"1","volume":"6","author":"R Junaid","year":"2018","unstructured":"Junaid R, Johannes ML, Gettinger SN (2018) Oncolytic virus immunotherapy: future prospects for oncology. JITC 6(140):1\u201313","journal-title":"JITC"},{"key":"6752_CR171","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2174\/1389450122666210203194036","volume":"22","author":"AR Kumar","year":"2021","unstructured":"Kumar AR, Devan AR, Nair B, Nath LR (2021) Anti-VEGF mediated immunomodulatory role of phytochemicals: scientific exposition for plausible HCC treatment. Curr Drug Targets 22:1288","journal-title":"Curr Drug Targets"},{"issue":"1","key":"6752_CR172","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00281-018-0714-9","volume":"41","author":"VS Emmett","year":"2019","unstructured":"Emmett VS (2019) Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Semin Immunopathol 41(1):21\u201330","journal-title":"Semin Immunopathol"},{"key":"6752_CR173","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","volume":"10","author":"OK Duaa","year":"2019","unstructured":"Duaa OK, Heather JB, Silvia M (2019) Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front Immunol 10:453","journal-title":"Front Immunol"},{"key":"6752_CR174","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fphar.2018.00185","volume":"9","author":"W Yifan","year":"2018","unstructured":"Yifan W, Weiye D, Li N (2018) Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol 9:185","journal-title":"Front Pharmacol"},{"issue":"5","key":"6752_CR175","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3747\/co.25.4002","volume":"25","author":"N Asna","year":"2018","unstructured":"Asna N, Livoff A, Batash R (2018) Radiation therapy and immunotherapy: a potential combination in cancer treatment. Curr Oncol 25(5):454\u2013460","journal-title":"Curr Oncol"},{"key":"6752_CR176","first-page":"325","volume":"4","author":"EV Ralph","year":"2014","unstructured":"Ralph EV, Benjamin TC, Claire V (2014) Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 4:325","journal-title":"Front Oncol"},{"key":"6752_CR177","doi-asserted-by":"crossref","first-page":"v356","DOI":"10.1093\/annonc\/mdz249.001","volume":"30","author":"T Powles","year":"2019","unstructured":"Powles T, Balar A, Gravis G, Jones R, Ravaud A, Florence J, Grivas P, Petrylak DP, Galsky M, Carles J, Sridhar S (2019) An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies. Ann Oncol 30:v356\u2013v357","journal-title":"Ann Oncol"},{"issue":"12","key":"6752_CR178","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14737140.2019.1699407","volume":"19","author":"M Shuji","year":"2019","unstructured":"Shuji M (2019) Durvalumab for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther 19(12):1009\u20131016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"6752_CR179","first-page":"891","volume":"15","author":"MC Julie","year":"2019","unstructured":"Julie MC, James LG (2019) Product review: avelumab, an anti-PD-L1 antibody. Hum VaccinImmunother 15(4):891\u2013908","journal-title":"Hum VaccinImmunother"},{"issue":"92","key":"6752_CR180","first-page":"1","volume":"12","author":"A Akintunde","year":"2019","unstructured":"Akintunde A, Zoaib R (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(92):1\u201313","journal-title":"J Hematol Oncol"},{"key":"6752_CR181","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","volume":"17","author":"X Wu","year":"2019","unstructured":"Wu X, Gu Z, Chen Y (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J 17:661\u2013674","journal-title":"Comput Struct Biotechnol J"},{"key":"6752_CR182","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/CMAR.S151023","volume":"11","author":"P Rusquec","year":"2019","unstructured":"Rusquec P, Calbiac O, Robert M, Campone M, Frenel JS (2019) Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res 11:4297\u20134312","journal-title":"Cancer Manag Res"},{"issue":"128","key":"6752_CR183","first-page":"1","volume":"6","author":"V Verma","year":"2018","unstructured":"Verma V, Sprave T, Haque W (2018) A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer 6(128):1\u201315","journal-title":"J Immunother Cancer"},{"issue":"1","key":"6752_CR184","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18(1):155","journal-title":"Mol Cancer"},{"issue":"1","key":"6752_CR185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11(1):39","journal-title":"J Hematol Oncol"},{"key":"6752_CR186","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2147\/TCRM.S145039","volume":"14","author":"MD Jain","year":"2018","unstructured":"Jain MD, Bachmeier CA, Phuoc VH, Chavez JC (2018) Axicabtageneciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed\/refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ther Clin Risk Manag 14:1007\u20131017","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"6752_CR187","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","volume":"6","author":"MM Boyiadzis","year":"2018","unstructured":"Boyiadzis MM, Dhodapkar MV, Brentjens RJ (2018) Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer 6(1):137","journal-title":"J Immunother Cancer"},{"issue":"68","key":"6752_CR188","first-page":"1","volume":"5","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Bellmunt J, Galsky MD (2017) Society for Immunotherapy of Cancer consensus statement on Immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(68):1\u201316","journal-title":"J Immunother Cancer"},{"issue":"3","key":"6752_CR189","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ (2019) Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov 18(3):175\u2013196","journal-title":"Nat Rev Drug Discov"},{"key":"6752_CR190","first-page":"79","volume":"4","author":"RN Amaria","year":"2015","unstructured":"Amaria RN, Reuben A, Cooper ZA, Wargo JA (2015) Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther 4:79\u201389","journal-title":"Immunotargets Ther"},{"key":"6752_CR191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/970315","volume":"2014","author":"NR Asmana","year":"2014","unstructured":"Asmana NR (2014) Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo) 2014:1\u20139","journal-title":"Scientifica (Cairo)"},{"issue":"4","key":"6752_CR192","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/0253-7613.161249","volume":"47","author":"AK Bubna","year":"2015","unstructured":"Bubna AK (2015) Imiquimod - Its role in the treatment of cutaneous malignancies. Indian J Pharmacol 47(4):354\u2013359","journal-title":"Indian J Pharmacol"},{"issue":"7","key":"6752_CR193","first-page":"452","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL (2017) Cancer Immunotherapy, part 2: efficacy, safety, and other clinical considerations. Phar Ther 42(7):452\u2013463","journal-title":"Phar Ther"},{"issue":"6","key":"6752_CR194","first-page":"650","volume":"63","author":"A Coulson","year":"2014","unstructured":"Coulson A, Levy A, Gossell WM (2014) Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J 63(6):650\u2013654","journal-title":"West Indian Med J"},{"issue":"9","key":"6752_CR195","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1358\/dot.2015.51.9.2383044","volume":"51","author":"FJ Kohlhapp","year":"2015","unstructured":"Kohlhapp FJ, Zloza A, Kaufman HL (2015) Talimogenelaherparepvec (T-VEC) as cancer immunotherapy. Drugs Today (Barc) 51(9):549\u2013558","journal-title":"Drugs Today (Barc)"},{"issue":"4","key":"6752_CR196","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1078155215618770","volume":"22","author":"MJ Newman","year":"2016","unstructured":"Newman MJ, Benani DJ (2016) A review of blinatumomab, a novel immunotherapy. J Oncol Pharm Pract 22(4):639\u2013645","journal-title":"J Oncol Pharm Pract"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06752-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:50:31Z","timestamp":1725943831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06752-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":196,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6752"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06752-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}